vs

Side-by-side financial comparison of Eventbrite, Inc. (EB) and 4D Molecular Therapeutics, Inc. (FDMT). Click either name above to swap in a different company.

4D Molecular Therapeutics, Inc. is the larger business by last-quarter revenue ($85.1M vs $73.5M, roughly 1.2× Eventbrite, Inc.). 4D Molecular Therapeutics, Inc. runs the higher net margin — 22.8% vs -11.1%, a 33.9% gap on every dollar of revenue. On growth, 4D Molecular Therapeutics, Inc. posted the faster year-over-year revenue change (8508900.0% vs -3.9%). 4D Molecular Therapeutics, Inc. produced more free cash flow last quarter ($28.5M vs $-60.9M). Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs -7.7%).

Eventbrite is an American live events marketplace and website. The service allows users to browse, create, and promote local events. It is free to publish unlimited events of any size on Eventbrite.

4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.

EB vs FDMT — Head-to-Head

Bigger by revenue
FDMT
FDMT
1.2× larger
FDMT
$85.1M
$73.5M
EB
Growing faster (revenue YoY)
FDMT
FDMT
+8508903.9% gap
FDMT
8508900.0%
-3.9%
EB
Higher net margin
FDMT
FDMT
33.9% more per $
FDMT
22.8%
-11.1%
EB
More free cash flow
FDMT
FDMT
$89.3M more FCF
FDMT
$28.5M
$-60.9M
EB
Faster 2-yr revenue CAGR
FDMT
FDMT
Annualised
FDMT
5412.6%
-7.7%
EB

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
EB
EB
FDMT
FDMT
Revenue
$73.5M
$85.1M
Net Profit
$-8.2M
$19.4M
Gross Margin
68.1%
Operating Margin
-12.4%
17.3%
Net Margin
-11.1%
22.8%
Revenue YoY
-3.9%
8508900.0%
Net Profit YoY
2.5%
139.1%
EPS (diluted)
$-0.08
$0.43

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EB
EB
FDMT
FDMT
Q4 25
$73.5M
$85.1M
Q3 25
$71.7M
$90.0K
Q2 25
$72.8M
$15.0K
Q1 25
$73.8M
$14.0K
Q4 24
$76.5M
$1.0K
Q3 24
$77.8M
$3.0K
Q2 24
$84.6M
$5.0K
Q1 24
$86.3M
$28.0K
Net Profit
EB
EB
FDMT
FDMT
Q4 25
$-8.2M
$19.4M
Q3 25
$6.4M
$-56.9M
Q2 25
$-2.1M
$-54.7M
Q1 25
$-6.6M
$-48.0M
Q4 24
$-8.4M
Q3 24
$-3.8M
$-43.8M
Q2 24
$1.1M
$-35.0M
Q1 24
$-4.5M
$-32.4M
Gross Margin
EB
EB
FDMT
FDMT
Q4 25
68.1%
Q3 25
67.9%
Q2 25
67.5%
Q1 25
66.9%
Q4 24
68.2%
Q3 24
68.5%
Q2 24
70.9%
Q1 24
71.0%
Operating Margin
EB
EB
FDMT
FDMT
Q4 25
-12.4%
17.3%
Q3 25
-1.3%
-67983.3%
Q2 25
-8.7%
-396373.3%
Q1 25
-13.2%
-383007.1%
Q4 24
-10.2%
Q3 24
-11.5%
-1704400.0%
Q2 24
-7.6%
-849120.0%
Q1 24
-8.8%
-136200.0%
Net Margin
EB
EB
FDMT
FDMT
Q4 25
-11.1%
22.8%
Q3 25
8.9%
-63195.6%
Q2 25
-2.9%
-364386.7%
Q1 25
-9.0%
-342657.1%
Q4 24
-11.0%
Q3 24
-4.8%
-1461433.3%
Q2 24
1.3%
-699060.0%
Q1 24
-5.2%
-115717.9%
EPS (diluted)
EB
EB
FDMT
FDMT
Q4 25
$-0.08
$0.43
Q3 25
$0.06
$-1.01
Q2 25
$-0.02
$-0.98
Q1 25
$-0.07
$-0.86
Q4 24
$-0.09
Q3 24
$-0.04
$-0.79
Q2 24
$0.01
$-0.63
Q1 24
$-0.05
$-0.66

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EB
EB
FDMT
FDMT
Cash + ST InvestmentsLiquidity on hand
$299.9M
$402.7M
Total DebtLower is stronger
$144.4M
Stockholders' EquityBook value
$179.1M
$505.7M
Total Assets
$647.2M
$566.7M
Debt / EquityLower = less leverage
0.81×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EB
EB
FDMT
FDMT
Q4 25
$299.9M
$402.7M
Q3 25
$305.1M
Q2 25
$293.2M
Q1 25
$321.4M
Q4 24
$441.5M
$424.9M
Q3 24
$24.7M
$501.9M
Q2 24
$56.7M
$541.9M
Q1 24
$113.7M
$525.9M
Total Debt
EB
EB
FDMT
FDMT
Q4 25
$144.4M
Q3 25
$174.9M
Q2 25
$241.3M
Q1 25
$241.0M
Q4 24
$240.7M
Q3 24
$240.4M
Q2 24
$358.7M
Q1 24
$358.2M
Stockholders' Equity
EB
EB
FDMT
FDMT
Q4 25
$179.1M
$505.7M
Q3 25
$189.1M
$369.0M
Q2 25
$177.2M
$420.9M
Q1 25
$173.3M
$469.7M
Q4 24
$170.2M
$510.6M
Q3 24
$179.8M
$552.9M
Q2 24
$176.2M
$588.3M
Q1 24
$184.1M
$600.6M
Total Assets
EB
EB
FDMT
FDMT
Q4 25
$647.2M
$566.7M
Q3 25
$744.6M
$424.0M
Q2 25
$784.1M
$473.6M
Q1 25
$812.3M
$515.7M
Q4 24
$752.3M
$560.4M
Q3 24
$817.4M
$604.0M
Q2 24
$894.5M
$620.1M
Q1 24
$952.2M
$629.9M
Debt / Equity
EB
EB
FDMT
FDMT
Q4 25
0.81×
Q3 25
0.92×
Q2 25
1.36×
Q1 25
1.39×
Q4 24
1.41×
Q3 24
1.34×
Q2 24
2.04×
Q1 24
1.95×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EB
EB
FDMT
FDMT
Operating Cash FlowLast quarter
$-60.8M
$28.6M
Free Cash FlowOCF − Capex
$-60.9M
$28.5M
FCF MarginFCF / Revenue
-82.8%
33.5%
Capex IntensityCapex / Revenue
0.0%
0.1%
Cash ConversionOCF / Net Profit
1.47×
TTM Free Cash FlowTrailing 4 quarters
$17.6M
$-109.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EB
EB
FDMT
FDMT
Q4 25
$-60.8M
$28.6M
Q3 25
$36.7M
$-46.5M
Q2 25
$-17.5M
$-43.4M
Q1 25
$59.4M
$-47.8M
Q4 24
$-45.3M
$-134.6M
Q3 24
$44.6M
$-29.4M
Q2 24
$-32.3M
$-30.2M
Q1 24
$68.6M
$-29.1M
Free Cash Flow
EB
EB
FDMT
FDMT
Q4 25
$-60.9M
$28.5M
Q3 25
$36.6M
$-46.6M
Q2 25
$-17.5M
$-43.4M
Q1 25
$59.4M
$-48.4M
Q4 24
$-45.3M
$-138.4M
Q3 24
$44.4M
$-31.2M
Q2 24
$-32.4M
$-30.6M
Q1 24
$68.2M
$-29.8M
FCF Margin
EB
EB
FDMT
FDMT
Q4 25
-82.8%
33.5%
Q3 25
51.1%
-51765.6%
Q2 25
-24.1%
-289620.0%
Q1 25
80.4%
-345635.7%
Q4 24
-59.2%
-13837100.0%
Q3 24
57.1%
-1038966.7%
Q2 24
-38.3%
-611840.0%
Q1 24
79.1%
-106421.4%
Capex Intensity
EB
EB
FDMT
FDMT
Q4 25
0.0%
0.1%
Q3 25
0.0%
101.1%
Q2 25
0.0%
440.0%
Q1 25
0.1%
4507.1%
Q4 24
0.0%
378600.0%
Q3 24
0.2%
59266.7%
Q2 24
0.1%
6980.0%
Q1 24
0.4%
2535.7%
Cash Conversion
EB
EB
FDMT
FDMT
Q4 25
1.47×
Q3 25
5.76×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
-30.37×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EB
EB

US$52.0M71%
Other$21.6M29%

FDMT
FDMT

Segment breakdown not available.

Related Comparisons